The drug maker on Tuesday, December 9, said its wholly-owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates, entered into a strategic partnership with Formycon AG for the exclusive licensing and supply of FYB206, a biosimilar of Keytruda (pembrolizumab), in the US and Canada.
